Suleman Kausar, Mushtaq Ali Hassan, Haque Emaan, Badran Ahmed Ali, Ajarim Dahish, Elashwah Ahmed Mohammed, Gad Ahmed Mostafa, Abdelsamad Amgad Shaheen, Omar Ayman, Khan Khurshid Ahmed, Al-Tweigeri Taher, Elshentenawy Ayman, Alsayed Adher
Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Associate Professor for Al Faisal University, Riyadh, Saudi Arabia.
Breast Care (Basel). 2021 Feb;16(1):59-65. doi: 10.1159/000506824. Epub 2020 Apr 6.
Human epidermal growth factor receptor 2 (HER-2) targeted therapy regimens can improve tumor response in HER-2-positive metastatic breast cancer (MBC), with overall survival benefits.
We evaluated the efficacy of dual HER-2 blockade combined with chemotherapy for HER-2-positive MBC patients as a first-line therapy in our patient population.
We identified 75 patients at King Faisal Specialist Hospital and Research Center that received trastuzumab, pertuzumab, and docetaxel as a first-line therapy in HER-2 positive MBC in 2013-2016.
Median age at diagnosis was 45 years; 54.7% were estrogen receptor (ER)-positive. 10% of patients presented with only bone metastasis. The median follow-up time was 36 months with an objective response rate of 74.7% (complete response [CR] 18.7%; partial response [PR] 56%). The 5-year progression-free survival (PFS) and overall survival (OS) were 21% and 71.9% respectively, with a median PFS of 36 months (95% confidence interval [CI] 23.6-48.4). The 5-year OS for ER-negative and ER-positive patients was 93.9% and 59.4% respectively ( = 0.189); 23 patients experienced grade 1/2 toxicity and 2 patients had grade 3/4 toxicity. In terms of OS and PFS, the site of metastasis did not make any significant difference.
First line pertuzumab, trastuzumab, and docetaxel for HER-2-positive MBC patients was found to be an effective and safe therapy in the Saudi population. This finding was consistent with the results seen in the CLEOPATRA trials.
人表皮生长因子受体2（HER-2）靶向治疗方案可改善HER-2阳性转移性乳腺癌（MBC）的肿瘤反应，并带来总生存获益。
我们评估了双重HER-2阻断联合化疗作为一线治疗方案对我们患者群体中HER-2阳性MBC患者的疗效。
我们在费萨尔国王专科医院及研究中心确定了75例于2013年至2016年期间接受曲妥珠单抗、帕妥珠单抗和多西他赛作为HER-2阳性MBC一线治疗的患者。
诊断时的中位年龄为45岁；54.7%为雌激素受体（ER）阳性。10%的患者仅出现骨转移。中位随访时间为36个月，客观缓解率为74.7%（完全缓解[CR]18.7%；部分缓解[PR]56%）。5年无进展生存期（PFS）和总生存期（OS）分别为21%和71.9%，中位PFS为36个月（95%置信区间[CI]23.6 - 48.4）。ER阴性和ER阳性患者的5年OS分别为93.9%和59.4%（P = 0.189）；23例患者出现1/2级毒性，2例患者出现3/4级毒性。在OS和PFS方面，转移部位没有显著差异。
对于HER-2阳性MBC患者，一线使用帕妥珠单抗、曲妥珠单抗和多西他赛在沙特人群中被发现是一种有效且安全的治疗方法。这一发现与CLEOPATRA试验的结果一致。
